A5100766043- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Platelet Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer Treatment and Pharmacology
- Blood Coagulation and Thrombosis Mechanisms
- Acute Ischemic Stroke Management
- Central Venous Catheters and Hemodialysis
- Pharmacovigilance and Adverse Drug Reactions
- Systemic Lupus Erythematosus Research
- Diagnosis and Treatment of Venous Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myocardial Infarction Research
- Vitamin K Research Studies
- Multiple Myeloma Research and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiac, Anesthesia and Surgical Outcomes
- Pharmacogenetics and Drug Metabolism
- Case Reports on Hematomas
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 Clinical Research Studies
- Healthcare cost, quality, practices
- Peripheral Artery Disease Management
University of Almería
2025
EsSALUD
2025
University of Washington
2015-2024
National Training Service
2024
Kingston University
2024
University Medical Center Utrecht
2023
Mayo Clinic in Arizona
2023
Mayo Clinic
2023
SUNY Downstate Health Sciences University
2023
Seattle University
2013-2022
Vitamin K antagonists are highly effective in preventing stroke patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of similar population comparison aspirin.In this randomized, double-blind trial, we compared apixaban (at dose 5 mg twice daily) warfarin (target international normalized ratio, 2.0 3.0) 18,201 and at least one additional for stroke. The primary outcome was ischemic or...
Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of with direct oral anticoagulant agents unclear.
It is uncertain whether bridging anticoagulation necessary for patients with atrial fibrillation who need an interruption in warfarin treatment elective operation or other invasive procedure. We hypothesized that forgoing would be noninferior to low-molecular-weight heparin the prevention of perioperative arterial thromboembolism and superior respect major bleeding.We performed a randomized, double-blind, placebo-controlled trial which, after therapy, were randomly assigned receive therapy...
Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these is uncertain.In this double-blind, randomized trial involving high-risk ambulatory with (Khorana score ≥2, on a scale from 0 to 6, higher scores indicating thromboembolism), we randomly assigned without deep-vein thrombosis screening receive rivaroxaban (at dose 10 mg) or placebo daily up 180 days, every 8 weeks. The primary efficacy end...
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result cytokine storm, systemic inflammatory response and coagulopathy prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular (DIC), COVID-19- induced (CIC) appears be more prothrombotic than hemorrhagic. It has been postulated CIC may an uncontrolled immunothrombotic COVID-19, there growing evidence venous arterial...
Abstract Background: Venous thromboembolism (VTE) is a common source of perioperative morbidity and mortality. Objective: These evidence-based guidelines from the American Society Hematology (ASH) intend to support decision making about preventing VTE in patients undergoing surgery. Methods: ASH formed multidisciplinary guideline panel balanced minimize bias conflicts interest. The McMaster University GRADE Centre supported guideline-development process, including performing systematic...
<h3>Background</h3> Significant uncertainty surrounds the treatment of patients who must discontinue warfarin sodium therapy before an invasive procedure. In part, results from lack published information about risk thromboembolism associated with short-term interruption. We aimed to assess frequency and bleeding within a large cohort whose was temporarily withheld for outpatient <h3>Methods</h3> This prospective, observational study performed at 101 sites (primarily community-based physician...
Patients who not only survive a warfarin-associated gastrointestinal tract bleeding (GIB) event but also have an ongoing risk for thromboembolism present 2 clinical dilemmas: whether and when to resume anticoagulation. The objective of this study was determine the incidence thrombosis, recurrent GIB, death, as well time resumption anticoagulant therapy, during 90 days following GIB event.In retrospective, cohort using administrative databases, patients experiencing warfarin therapy were...
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. This international multidisciplinary initiative included 4 phases: 1) Phase I, generation surveys literature review; 2) II, reduction modified Delphi nominal group technique exercises; 3) III, definition, further guidance real-world patient scenarios, weighting via consensus-based...
<h3>Objective</h3> To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. <h3>Methods</h3> This international multidisciplinary initiative included four phases: (1) Phase I, generation surveys literature review; (2) II, reduction modified Delphi nominal group technique exercises; (3) III, definition, further guidance real-world patient...
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE. The absolute rate 3.4% lower edoxaban, whereas 2.9% higher. present analysis focuses on sites, clinical presentation, course events, associated tumour types. Major bleeds their severity (categories 1–4) were blindly adjudicated by a committee using priori defined criteria, data analysed safety...
Background: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and atrial fibrillation (AF). Methods: The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) versus warfarin receiving AF CHA 2 DS -VASc score ≥2. were randomly assigned 1:1 to 5 mg twice daily (2.5...